Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ) has provided an announcement.
KYORIN Pharmaceutical Co., Ltd. reported its financial results for the six months ended September 30, 2025, showing a 6.5% increase in net sales compared to the previous year. However, the company experienced a decline in operating and ordinary profit by 12.0% and 22.8%, respectively. Despite these challenges, the profit attributable to owners of the parent increased by 19.0%. The company maintains a strong equity ratio of 73.4% and plans to commence dividend payments on December 2, 2025. The forecast for the full fiscal year ending March 31, 2026, anticipates a decrease in net sales and profits, reflecting ongoing challenges in the market.
The most recent analyst rating on (JP:4569) stock is a Hold with a Yen1653.00 price target. To see the full list of analyst forecasts on KYORIN Pharmaceutical Co.,Ltd. stock, see the JP:4569 Stock Forecast page.
More about KYORIN Pharmaceutical Co.,Ltd.
KYORIN Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of pharmaceutical products. The company is headquartered in Japan and is listed on the Tokyo Stock Exchange.
Average Trading Volume: 100,635
Technical Sentiment Signal: Sell
Current Market Cap: Yen73.75B
For an in-depth examination of 4569 stock, go to TipRanks’ Overview page.